Welcome to our dedicated page for KAIROS PHARMA news (Ticker: KAPA), a resource for investors and traders seeking the latest updates and insights on KAIROS PHARMA stock.
Kairos Pharma Ltd (NYSE American: KAPA) is a clinical-stage biopharmaceutical company advancing precision oncology therapies targeting complex challenges like drug resistance. This page aggregates official press releases, clinical trial developments, and strategic partnership announcements to keep stakeholders informed.
Investors and researchers will find timely updates on KAPA's investigational therapies, biomarker validation progress, and regulatory milestones. Content spans clinical trial results, FDA submissions, and diagnostic partnership developments, providing a comprehensive view of the company's scientific trajectory.
All materials are sourced directly from verified company communications, ensuring accuracy for those monitoring advancements in personalized cancer treatments. Bookmark this page for streamlined access to KAPA's latest innovations in structural biology-driven therapeutics and companion diagnostic research.
Kairos Pharma (NYSE American: KAPA) has announced its participation in the 13th AACR-JCA Joint Conference in Maui, Hawaii. The clinical-stage biopharmaceutical company will present a talk titled 'KROS 101: A Next-Generation GITR Agonist Boosting Anti-Tumor T Cell Responses and Reprogramming the Tumor Microenvironment' during the plenary session on February 5, 2025, at 4:00 PM local time.
The conference, 'From Cancer Discovery Science to Therapeutic Innovation,' scheduled for February 1-5, 2025, is jointly organized by the American Association for Cancer Research (AACR) and Japanese Cancer Association (JCA). This prestigious meeting series brings together leading researchers from the United States, Japan, and worldwide to share findings and present latest advances in basic, translational, and clinical cancer research.
Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company, shared an update on its business milestones for 2024 and the outlook for 2025.
Key highlights from 2024:
- Closing of the Initial Public Offering and listing on the NYSE American on September 16, 2024.
- Agreement with PreCheck Health Services to develop a biomarker panel for ENV105 targeting cancer drug resistance in prostate and lung cancer.
- Addition of City of Hope Cancer Center to the Phase 2 trial of ENV105 for castrate-resistant prostate cancer.
- First patient dosed in combination therapy of ENV105 and Osimertinib for EGFR-driven lung cancer.
- Initiation of research coverage by EF Hutton and Rodman and Renshaw.
For 2025, Kairos expects:
- Continuation of Phase 2 and Phase 1 trials of ENV105 in prostate and non-small cell lung cancer, respectively.
- Safety data readouts for both trials, with prostate cancer data expected in the first half of 2025 and NSCLC data by year-end.
- Pre-IND studies of KROS 101 and initiation of partnering discussions.
The company raised $3.5 million through a PIPE transaction and expanded patent coverage to protect their technologies. Kairos aims to provide significant shareholder value through continued development and presentation of their clinical data.
Kairos Pharma (NYSE American: KAPA) has announced its participation in the upcoming Lytham Partners Investor Healthcare Summit, scheduled for January 13, 2025. The company's leadership, including CEO John S. Yu, M.D., and Chief Scientific Officer Neil Bhowmick, will deliver a corporate overview during a virtual presentation at 2:00 PM ET.
The management team will be available for one-on-one virtual meetings throughout the event. Interested parties can arrange meetings through Lytham Partners or register directly via the event website. The presentation will be accessible through a webcast, with replay options available after the event.
Kairos Pharma (NYSE American:KAPA), a clinical stage biotechnology company, has announced its upcoming participation in The Microcap Conference 2025. The event will be held from January 28-30, 2025, at the Borgata Hotel Spa & Casino in Atlantic City, NJ. During the conference, the company's management team will deliver a corporate presentation and conduct one-on-one meetings with institutional and individual investors to discuss recent developments, growth strategy, and investment opportunities.
Kairos Pharma (NYSE American: KAPA) announces the addition of City of Hope Cancer Center in Duarte, California to its Phase 2 clinical trial for ENV105 in castrate-resistant prostate cancer patients. The trial will compare apalutamide alone versus apalutamide+ENV105 combination therapy. This is the first of several planned new centers to be added. The expansion aims to test ENV105 in a broader patient population and identify blood markers for patient selection. The trial is supported by Kairos Pharma and a National Cancer Institute grant. Preclinical findings indicate ENV105 blocks hormone therapy resistance mechanisms.
Kairos Pharma (KAPA) has received approval for dual listing on Upstream, a MERJ Exchange market and global securities trading app. Trading will commence on November 26, 2024, at 10:00am ET under the ticker 'KAPA'. The dual listing aims to provide access to global investors outside the U.S., enhance liquidity, and improve price discovery. The company's platform features real-time trading, settlement, and a transparent orderbook designed to prevent market manipulation. Dr. John Yu, CEO, emphasized the move aligns with their goal of building shareholder value while expanding their lead drug ENV105 for cancer treatments.
Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company, has announced its participation in the LD Micro Main Event XVII. The event is scheduled for October 28-30, 2024 at the Luxe Sunset Boulevard Hotel in Los Angeles.
Dr. John S. Yu, Chief Executive Officer of Kairos Pharma, will deliver a corporate overview during the conference. His presentation is set for Wednesday, October 30, 2024, at 12:00 PM PT.
Interested parties can register to watch the presentation online through the provided link: https://me24.sequireevents.com/
Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company, has announced its participation in the 2024 Maxim Healthcare Virtual Summit. The company's Chief Executive Officer, John S. Yu, M.D., will engage in a fireside chat with Jason McCarthy, Ph.D., Senior Managing Director and Head of Biotechnology Research at Maxim Group.
The virtual summit is scheduled to take place from October 15 to 17, 2024. Kairos Pharma's fireside chat is set for Thursday, October 17, 2024, at 1:00 PM ET. Interested parties can access the webcast of the event through the provided link: https://m-vest.com/events/healthcare-10152024.
This participation offers an opportunity for Kairos Pharma to share insights and updates with the investment community, potentially discussing their ongoing clinical-stage research and development in the biopharmaceutical sector.
Kairos Pharma (NYSE American: KAPA) has entered a collaboration with PreCheck Health Services Inc. to develop companion biomarkers for its cancer therapy, ENV105, targeting prostate and lung cancers. The partnership aims to enhance patient screening and therapy monitoring for Kairos Pharma's Phase 1 and Phase 2 clinical trials.
PreCheck will analyze biopsy tissues and circulating tumor cells from patients in ongoing trials, including a Phase 2 randomized trial in prostate cancer and a Phase 1 trial in lung cancer. The collaboration will use PreCheck's SolidTumorCheck+ platform for gene expression profiling of tumor biopsies.
The partnership focuses on developing an FDA-approved companion diagnostic for ENV105, which will help identify suitable patients for treatment in Phase 3 clinical trials. This collaboration is expected to advance personalized cancer treatment and improve patient outcomes.
Kairos Pharma (NYSE American: KAPA) has successfully closed its initial public offering, raising $6.2 million by selling 1,550,000 shares at $4.00 each. Trading began on September 16, 2024. The company plans to use the funds to advance its cancer therapeutics pipeline, including a Phase 1 trial for lung cancer and a Phase 2 trial for prostate cancer with its lead candidate ENV 105. Additionally, proceeds will support preclinical development of KROS 101, a small molecule agonist for GITR ligand. Underwriters have a 45-day option to purchase up to 232,500 additional shares. Boustead Securities led the offering, with EF Hutton and Sutter Securities as co-managers.
